ArticleTranslational pediatrics2026
Retrospective analysis of growth hormone effects on growth and adenoma volume in children with pituitary microadenoma.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pituitary microadenomas (PMs) are increasingly identified in children evaluated for growth or pubertal concerns; uncertainty about tumor behavior often delays growth hormone (GH) therapy. This study aimed to assess the efficacy and short-term safety of recombinant human growth hormone (rhGH) plus leuprorelin in children with PM. Methods: We retrospectively reviewed 22 children who received rhGH plus leuprorelin. Growth parameters, including height, bone age (BA), BA minus chronological age (CA), height standard deviation score (HtSDS), and predicted adult height (PAH), were compared before and after treatment using paired-sample Results: The mean durations of GH and leuprorelin treatment were 1.75 and 1.57 years, respectively. After therapy, BA-CA decreased from 1.08 to 0.40 years (Δ =-0.68 years; P<0.001), HtSDS increased by 0.41 (P=0.003), and PAH improved by 7.43 cm (P<0.001). FBG, FINS, and thyroid function markers (TSH, FT3, FT4) remained stable over 1 year. Tumor volume decreased by 2.72 mm Conclusions: Combined GH and leuprorelin enhances linear growth and delayed bone maturation in children with PM and compromised PAH, without promoting tumor growth or sustained IGF-1 elevation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.